Jiangxi Synergy Pharmaceutical (300636.SZ): Mirabegron and Empagliflozin have obtained GMP compliance certificates from the Australian Medicines and Therapeutics Administration.
Tonghe Pharmaceutical (300636.SZ) announced that it recently received the GMP compliance certificates for Mirabegron and Empagliflozin issued by the Therapeutic Goods Administration (TGA) of Australia. Mirabegron is a selective 3-adrenergic receptor agonist that increases bladder capacity and storage ability by activating 3-adrenergic receptors on the bladder detrusor muscle, and it is clinically used to treat symptoms of overactive bladder such as urinary urgency, urinary incontinence, and frequency. Empagliflozin is indicated for the treatment of type 2 diabetes.
Jiangxi Synergy Pharmaceutical (300636.SZ) announced that it has recently received the GMP compliance certificates for Mirabegron and Empagliflozin issued by the Therapeutic Goods Administration (TGA) of Australia. Mirabegron is a selective 3-adrenergic receptor agonist that enhances bladder filling and storage capacity by activating 3-adrenergic receptors on the bladder detrusor muscle. It is clinically used for the treatment of symptoms of overactive bladder, including urgency, frequency, and urge incontinence. Empagliflozin is indicated for the treatment of type 2 diabetes.
This is the company's first successful certification by the TGA, indicating that the company has obtained TGA recognition in aspects such as quality systems and production environment facilities. Australia is a member country of the Pharmaceutical Inspection Co-operation Scheme (PIC/S), and this certification will help the company continue to promote the development of the international market.
Related Articles
HING LEE (HK)(00396) issues profit warning, expecting a net loss of approximately HKD 1.6 million for the interim period, turning from profit to loss compared to the same period last year.
The real estate sector has entered the era of existing stock, and Xuhui (00884) is expected to break through by leveraging the synergy between its light and heavy business operations.
CHINA SHENGMU (01432): The Chinese stock abbreviation will be changed to CHINA SHENGMU-PF.
HING LEE (HK)(00396) issues profit warning, expecting a net loss of approximately HKD 1.6 million for the interim period, turning from profit to loss compared to the same period last year.
The real estate sector has entered the era of existing stock, and Xuhui (00884) is expected to break through by leveraging the synergy between its light and heavy business operations.
CHINA SHENGMU (01432): The Chinese stock abbreviation will be changed to CHINA SHENGMU-PF.
RECOMMEND
